36 results on '"Achim H.-P. Krauss"'
Search Results
2. Antiglaucoma EP2Agonists: A Long Road That Led Somewhere
- Author
-
Achim H.-P. Krauss, David F. Woodward, Jenny W. Wang, W. Daniel Stamer, Elke Lütjen-Drecoll, and Carol B. Toris
- Subjects
0301 basic medicine ,Pharmacology ,03 medical and health sciences ,Ophthalmology ,030104 developmental biology ,0302 clinical medicine ,Political science ,030221 ophthalmology & optometry ,Subject (philosophy) ,Pharmacology (medical) ,Engineering ethics - Abstract
For >2 decades, EP2 agonists have been the subject of antiglaucoma research and development by scientists in industry and academia around the world. The road has led to the recent approval...
- Published
- 2019
3. Antiglaucoma EP
- Author
-
David F, Woodward, Jenny W, Wang, W Daniel, Stamer, E, Lütjen-Drecoll, Achim H-P, Krauss, and Carol B, Toris
- Subjects
Drug Delivery Systems ,Animals ,Humans ,Glaucoma ,Receptors, Prostaglandin E, EP2 Subtype ,Antihypertensive Agents - Abstract
For2 decades, EP
- Published
- 2019
4. A dual acting compound with latanoprost amide and nitric oxide releasing properties, shows ocular hypotensive effects in rabbits and dogs
- Author
-
David Gale, Francesco Impagnatiello, Wesley K. M. Chong, Samantha Carreiro, Minerva R. Batugo, Ganesh Prasanna, Ennio Ongini, Massimiliano Guzzetta, Achim H.-P. Krauss, S. Brambilla, Valentina Borghi, and Valerio Chiroli
- Subjects
Male ,Agonist ,Molsidomine ,genetic structures ,medicine.drug_class ,Vasodilator Agents ,Ocular hypertension ,Prostaglandin ,Pharmacology ,Dinoprost ,Nitric Oxide ,Nitric oxide ,Tonometry, Ocular ,Cellular and Molecular Neuroscience ,chemistry.chemical_compound ,Dogs ,Tandem Mass Spectrometry ,medicine ,Animals ,Potency ,Nitric Oxide Donors ,Latanoprost ,Antihypertensive Agents ,Aorta ,Chromatography, High Pressure Liquid ,Intraocular Pressure ,Nitrates ,Bimatoprost ,Chemistry ,Cloprostenol ,Glaucoma ,medicine.disease ,Amides ,eye diseases ,Sensory Systems ,Vasodilation ,Disease Models, Animal ,Ophthalmology ,Anesthesia ,Prostaglandins F, Synthetic ,Ocular Hypertension ,Rabbits ,medicine.drug - Abstract
The IOP lowering effects of NCX 139, a new chemical entity comprising latanoprost amide and a NO-donating moiety, were compared to those of the respective des-nitro analog in in vitro assays and in rabbit and dog models of ocular hypertension. The NO donor, molsidomine as well as the prostamide bimatoprost (Lumigan(®)) and the prostaglandin agonist, latanoprost (Xalatan(®)) were also investigated for comparison. NCX 139 but not its des-nitro analog resulted in NO-mediated vascular relaxant effect in pre-contracted rabbit aortic rings (EC(50)=0.70±0.06 μM; E(max)=80.6±2.9%). Like bimatoprost (IC(50)=3.07±1.3 μM) or latanoprost (IC(50)=0.48±0.15 μM), NCX 139 displaced (3)H-PGF2α binding on recombinant human prostaglandin-F (FP) receptors with an estimated potency of 0.77±0.13 μM. In transient ocular hypertensive rabbits, bimatoprost and latanoprost were not effective while molsidomine elicited a dose-dependent reduction of IOP confirming the responsiveness of rabbits to NO but not to FP receptor agonists. NCX 139 tested at a therapeutically relevant dose, significantly lowered IOP while the des-nitro analog was not effective (0.03% NCX 139, Δ(max)=-12.8±2.0 mmHg). In glaucomatous dogs, 0.03% NCX 139 decreased IOP to a greater extent compared to an equimolar dose of the respective des-nitro derivative (Δ(max)=-4.6±1.0 and -2.7±1.3 mmHg, respectively for NCX 139 and its des-nitro analog). Albeit with low potency, NCX 139 also resulted effective in normotensive dogs while it did not reduce IOP in normotensive rabbits. NCX 139, a compound targeting two different and important mechanisms, is endowed with ocular hypotensive effects more evident in hypertensive conditions which may be of interest in the search of more effective treatments for hypertensive glaucoma.
- Published
- 2011
5. In Vivo Evaluation of 11β-Hydroxysteroid Dehydrogenase Activity in the Rabbit Eye
- Author
-
Achim H.-P. Krauss, Ganesh Prasanna, Hovhannes J. Gukasyan, Cheng Hengmiao, David Gale, Scott Anderson, Samantha Carreiro, Terri Quenzer, Jennifer Lafontaine, and Cathie Xiang
- Subjects
Intraocular pressure ,medicine.medical_specialty ,Hydrocortisone ,genetic structures ,Administration, Topical ,Carbenoxolone ,Ocular hypertension ,Glaucoma ,Biology ,Eye ,Aqueous Humor ,Pharmacokinetics ,Tandem Mass Spectrometry ,In vivo ,Internal medicine ,11-beta-Hydroxysteroid Dehydrogenase Type 1 ,medicine ,Animals ,Pharmacology (medical) ,Glucocorticoids ,Intraocular Pressure ,Pharmacology ,Lagomorpha ,Dose-Response Relationship, Drug ,medicine.disease ,biology.organism_classification ,eye diseases ,Cortisone ,Ophthalmology ,Endocrinology ,Rabbits ,sense organs ,hormones, hormone substitutes, and hormone antagonists ,Chromatography, Liquid ,medicine.drug - Abstract
Steroids are used in a diverse range of conditions in clinical ophthalmology and one of the most significant complications is corticosteroid-induced glaucoma, which is characterized by an increase in intraocular pressure (IOP). 11beta-Hydroxysteroid dehydrogenase-1 (11beta-HSD1) is known to catalyze the interconversion of hormonally inactive cortisone to hormonally active cortisol and is widely expressed in the eye, particularly ciliary epithelium. Carbenoxolone (CBX), an 11beta-HSD1 inhibitor, has been shown to reduce IOP in healthy volunteers and patients with ocular hypertension (OHT). The purpose of this study was to: (1) develop an in vivo model for the assessment of cortisone to cortisol conversion in the eye, that is, 11beta-HSD1 activity and (2) assess the pharmacokinetic/pharmacodynamic relationship following topical treatment with 11beta-HSD1 inhibitors using an in vivo rabbit model.Potent and selective 11beta-HSD1 inhibitors were topically administered to the rabbit eye and exogenous cortisone to endogenous cortisol conversion in the eye was assessed in rabbits. Tissues were then evaluated for cortisone, cortisol, and 11beta-HSD1 inhibitor levels by LC/MS/MS. Concomitantly cortisol activity in ocular tissue samples was determined using a secondary mechanistic pLuc-GRE assay.Topical treatment with potent and selective 11beta-HSD1 inhibitors resulted in complete inhibition in the conversion of cortisone to cortisol in the rabbit eye as well as decreased pLuc-GRE luciferase activity. The reduction of cortisone conversion was time- and dose-dependent as well as dependent on dosing volume (suggestive of increased spillover and washout with greater dosing volume).In conclusion, topical delivery of 11beta-HSD1 inhibitors can reduce or inhibit the conversion of cortisone to cortisol in the eye, indicating that the rabbit eye possesses an active enzyme for glucocorticoid synthesis. Dosing concentration and volume play an important role in the pharmacokinetic and pharmacodynamic effects of topically delivering an 11beta-HSD1 inhibitor. The rabbit model is useful for mechanistically assessing the conversion of cortisone to cortisol in the eye.
- Published
- 2009
6. Identification of an antagonist that selectively blocks the activity of prostamides (prostaglandin-ethanolamides) in the feline iris
- Author
-
Craig Struble, Yariv Donde, Yanbin Liang, R. M. Burk, Charles E. Protzman, Achim H.-P. Krauss, D.F. Woodward, Jenny W. Wang, K Landsverk, and A.L. Nieves
- Subjects
Pharmacology ,Agonist ,medicine.medical_specialty ,medicine.drug_class ,Antagonist ,Prostaglandin ,Prostanoid ,Anandamide ,Receptor antagonist ,Endocannabinoid system ,chemistry.chemical_compound ,Endocrinology ,chemistry ,Internal medicine ,medicine ,lipids (amino acids, peptides, and proteins) ,Receptor - Abstract
Background and Purpose: The prostamides (prostaglandin-ethanolamides) and prostaglandin (PG) glyceryl esters are biosynthesized by COX-2 from the respective endocannabinoids anandamide and 2-arachidonyl glycerol. Agonist studies suggest that their pharmacologies are unique and unrelated to prostanoid receptors. This concept was further investigated using antagonists. Experimental Approach: The isolated feline iris was used as a key preparation, where prostanoid FP receptors and prostamide activity co-exist. Activity at human recombinant FP and other prostanoid receptors was determined using stable transfectants. Key Results: In the feline iris, AGN 204396 produced a rightward shift of the dose-response curves for prostamide F2α and the prostamide F2α analog bimatoprost but did not block the effects of PGF2α and synthetic FP receptor agonists. Studies on human recombinant prostanoid receptors confirmed that AGN 204396 did not behave as a prostanoid FP receptor antagonist. AGN 204396 exhibited no antagonism at DP and EP1-4, but was a highly effective TP receptor antagonist. Contrary to expectation, the FP receptor antagonist AL-8810 efficaciously contracted the cat iris. AGN 204396 did not affect AL-8810 induced contractions, demonstrating that AL-8810 and AGN 204396 are pharmacologically distinct. Unlike AL-8810, the ethylamide derivate of AL-8810 was not an agonist. Al-8810 did not block prostamide F2α activity. Finally, AGN 204396 did not block PGE2-glyceryl ester activity. Conclusions and Implications: The ability of AGN 204396 to selectively block prostamide responses suggests the existence of prostamide sensitive receptors as entities distinct from receptors recognizing PGF2α and PGE2-glyceryl ester. British Journal of Pharmacology (2007) 150, 342–352. doi:10.1038/sj.bjp.0706989
- Published
- 2007
7. Intraocular Pressure-Lowering Activity of NCX 470, a Novel Nitric Oxide-Donating Bimatoprost in Preclinical Models
- Author
-
Ennio Ongini, Achim H.-P. Krauss, Francesco Impagnatiello, Minerva R. Batugo, Ganesh Prasanna, Valentina Borghi, Carol B. Toris, and Elena Bastia
- Subjects
Male ,medicine.medical_specialty ,Intraocular pressure ,genetic structures ,Prostaglandin ,Ocular hypertension ,Pharmacology ,Nitric oxide ,Aqueous Humor ,chemistry.chemical_compound ,Ciliary body ,Dogs ,Tandem Mass Spectrometry ,Ophthalmology ,medicine ,Animals ,Nitric Oxide Donors ,Antihypertensive Agents ,Intraocular Pressure ,Bimatoprost ,business.industry ,Ciliary Body ,medicine.disease ,eye diseases ,Disease Models, Animal ,Macaca fascicularis ,medicine.anatomical_structure ,Prostaglandin F2alpha ,chemistry ,Ocular Hypertension ,sense organs ,Trabecular meshwork ,Rabbits ,business ,medicine.drug - Abstract
PURPOSE The prostaglandin F2alpha (PGF2α) analogue bimatoprost lowers intraocular pressure (IOP) by increasing uveoscleral outflow at doses shown to elicit redness of the eye. With the aim to enhance the IOP-lowering effect of bimatoprost we studied NCX 470 [(S,E)-1-((1R,2R,3S,5R)-2-((Z)-7-(ethylamino)-7-oxohept-2-enyl)-3,5-dihydroxycyclopentyl)-5-phenylpent-1-en-3-yl 6-(nitrooxy)hexanoate], a dual-acting compound combining bimatoprost with nitric oxide (NO) known to mainly act via relaxation of trabecular meshwork and Schlemm's canal. METHODS New Zealand white rabbits with transient hypertonic saline-induced IOP elevation (tOHT-rabbits), cynomolgus monkeys with laser-induced ocular hypertension (OHT-monkeys), and normotensive dogs (ONT-dogs) were used. The levels of NCX 470, bimatoprost, and bimatoprost acid were determined in aqueous humor (AH), cornea (CR), and iris/ciliary body (ICB) by liquid chromatography-mass spectrometry/mass (LC-MS/MS), while cGMP in AH and ICB was monitored using an enzyme immunoassay (EIA) kit in pigmented Dutch Belted rabbits. RESULTS NCX 470 (0.14%, 30 μL) lowered IOP in tOHT-rabbits with an E(max) of -7.2 ± 2.8 mm Hg at 90 minutes. Bimatoprost at equimolar dose (0.1%, 30 μL) was noneffective in this model. NCX 470 (0.042%, 30 μL) was more effective than equimolar (0.03%, 30 μL) bimatoprost in ONT-dogs (IOP change, -5.4 ± 0.7 and -3.4 ± 0.7 mm Hg, respectively, P < 0.05) and in OHT-monkeys (IOP change, -7.7 ± 1.4 and -4.8 ± 1.7 mm Hg, respectively, P < 0.05) at 18 hours post dosing. NCX 470 (0.042%, 30 μL) or bimatoprost (0.03%, 30 μL) resulted in similar bimatoprost acid exposure in AH, CR, and ICB while cGMP was significantly increased in AH and ICB at 18 and 24 hours after NCX 470 dosing. CONCLUSIONS NCX 470 lowers IOP more than equimolar bimatoprost in three animal models of glaucoma by activating PGF2α and NO/cGMP signaling pathways.
- Published
- 2015
8. Stimulation of cannabinoid (CB1) and prostanoid (EP2) receptors opens BKCa channels and relaxes ocular trabecular meshwork
- Author
-
Friederike Stumpff, Lars Choritz, Hagen Thieme, Rita Rosenthal, Susann Meissner, Marianne Boxberger, Michael Wiederholt, and Achim H.-P. Krauss
- Subjects
Patch-Clamp Techniques ,medicine.medical_treatment ,8-Bromo Cyclic Adenosine Monophosphate ,Potassium Channels, Calcium-Activated ,Piperidines ,Receptor, Cannabinoid, CB1 ,Cyclic AMP ,Cells, Cultured ,Endothelin-1 ,Chemistry ,Prostanoic Acids ,Middle Aged ,Iberiotoxin ,Calcium Channel Blockers ,Stimulation, Chemical ,Sensory Systems ,Potassium channel ,medicine.anatomical_structure ,Ion Channel Gating ,medicine.drug ,Adult ,AM251 ,Agonist ,medicine.medical_specialty ,Carbachol ,medicine.drug_class ,Morpholines ,Cholinergic Agonists ,In Vitro Techniques ,Naphthalenes ,Contractility ,Cellular and Molecular Neuroscience ,Trabecular Meshwork ,Internal medicine ,medicine ,Animals ,Humans ,Receptors, Prostaglandin E ,Aged ,Cannabinoids ,Cyclohexanols ,Benzoxazines ,Ophthalmology ,Endocrinology ,15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid ,Pyrazoles ,Calcium ,Cattle ,Trabecular meshwork ,Cannabinoid ,Peptides - Abstract
Prostanoids and cannabinoids have ocular hypotensive and neuroprotective properties. The effect of the prostanoid AH13205 (EP2), the thromboxane-mimetic U46619, the cannabinoid (CB) agonists WIN55212-2 and CP 55,940, endothelin-1 (ET-1) and 8-bromo-cAMP on the membrane currents of trabecular meshwork (TM) cells were measured using the patch-clamp technique and compared to their effects on TM contractility. Previous studies show relaxation of TM to AH 13205 and other substances that elevate cAMP, while U46619 and endothelin-1 contract TM. This study shows that after contraction (100%) with carbachol (10−6 m ), the CB agonist CP 55,940 dose-dependently reduced contractility to 83±4% (n=9) (10−6 m ) and 61±10%, (n=7) (10−5 m ). In the presence of both the CB1 antagonist AM251 (10−6 m ) and CP 55,940 (10−5 m ), the contractile response to carbachol reached 84±3% (n=6) of the original level. In patch-clamp experiments, membrane permeable 8-bromo-cAMP (10−4 m ) had no effect on currents of TM cells. In contrast, AH 13205 and two cannabinoids reversibly enhanced outward current through high-conductance Ca2+-activated K+ channels (BKCa, BK, maxi-K) to the following values (in % of the initial value at 100 mV): AH 13205 (10−5 m ): 200±28% (n=6), CP 55,940 (10−6 m ): 196±33% (n=7), CP 55,940 (10−5 m ): 484±113% (n=7), WIN55212-2 (10−5 m ): 205±41% (n=10). Iberiotoxin (10−7 m ) completely blocked these responses. The current response to CP 55,940 (10−5 m ) could be partially blocked by the CB1 antagonist AM251 (10−6 m ). Conversely, the contractile agents in this study either caused a transient reduction in outward current (ET-1(5×10−8 m )) or had no effect (U46619 (10−6 m )). We conclude that stimulation of EP2 and CB1 receptors in TM is coupled to the activation of BKCa channels via a non-diffusible second messenger cascade. This effect may contribute to the relaxant activity of EP2 and CB1 agonists in isolated TM strips, modulating ocular outflow.
- Published
- 2005
9. Comparison of Prostaglandin F2α, Bimatoprost (Prostamide), and Butaprost (EP2 Agonist) on Cyr61 and Connective Tissue Growth Factor Gene Expression
- Author
-
Victor M. Guzman, Yanbin Liang, Albert J. Evinger, Charles E. Protzman, Chen Li, David F. Woodward, and Achim H.-P. Krauss
- Subjects
Agonist ,medicine.medical_specialty ,medicine.drug_class ,Prostaglandin E2 receptor ,Gene Expression ,Iris ,Prostaglandin ,In Vitro Techniques ,Biology ,Dinoprost ,Biochemistry ,Cell Line ,Immediate-Early Proteins ,chemistry.chemical_compound ,Trabecular Meshwork ,Internal medicine ,medicine ,Animals ,Humans ,RNA, Messenger ,Alprostadil ,Promoter Regions, Genetic ,Receptor ,Molecular Biology ,Cells, Cultured ,Oligonucleotide Array Sequence Analysis ,integumentary system ,Bimatoprost ,Ciliary Body ,Connective Tissue Growth Factor ,Cloprostenol ,Glaucoma ,Cell Biology ,Amides ,Lipids ,Up-Regulation ,Cell biology ,CTGF ,Kinetics ,Endocrinology ,chemistry ,CYR61 ,Cats ,Intercellular Signaling Peptides and Proteins ,Signal transduction ,Cysteine-Rich Protein 61 ,Signal Transduction ,medicine.drug - Abstract
Connective tissue growth factor (CTGF) and Cyr61 (cysteine-rich angiogenic protein 61) are members of the CCN gene family that encode multifunctional, extracellular matrix-associated signaling proteins. Because the mechanism of action of certain anti-glaucoma drugs involves extracellular matrix remodeling of ocular ciliary muscle, with a resultant increase in drainage of aqueous humor from the eye, we compared the effects of three pharmacologically distinct ocular hypotensive agents on Cyr61 and CTGF gene expression. Thus, prostaglandin F2alpha (PGF2alpha) (FP receptor agonist), Butaprost (EP2 receptor agonist), and Bimatoprost (a prostamide) were compared. Using Affymetrix gene chip technology, we first identified that PGF2alpha dramatically up-regulated Cyr61 and CTGF mRNA expression in HEK 293/EBNA cells (hFP-HEK 293/EBNA). Northern blot further confirmed the Cyr61 and CTGF up-regulation is in a dose- and time-dependent manner. PGF2alpha-induced up-regulation of Cyr61 appeared to exclusively involve the Rho pathway, and up-regulation of CTGF was via multiple intracellular pathways. Because prostamide receptors are, to date, defined only at the pharmacological level, Bimatoprost effects on Cyr61 and CTGF were studied in the isolated feline iris sphincter preparation, a tissue highly responsive to prostamides. Both PGF2alpha and Bimatoprost up-regulated Cyr61 mRNA expression in the cat iris tissue. Only PGF2alpha up-regulated CTGF mRNA expression in the cat iris. Therefore, PGF2alpha and Bimatoprost appear to interact with different receptors populations in the cat iris, according to their markedly different effects on CTGF. Activation of prostaglandin EP2 receptors (Gs-coupled) also up-regulated Cyr61 but not CTGF mRNA expression in the isolated cat iris. Similar data were observed in human primary ciliary smooth muscle cells. Thus, despite quite different signal transduction pathways, FP receptor stimulation up-regulates CTGF and Cyr61. The prostamide analog Bimatoprost and an EP2-selective agonist affects only Cyr61.
- Published
- 2003
10. Pharmacological Characterization of a Novel Antiglaucoma Agent, Bimatoprost (AGN 192024)
- Author
-
Charles E. Protzman, Alex Kharlamb, Chen Li, Achim H.-P. Krauss, Karen M. Kedzie, Steven W. Andrews, Heather A. Krauss, Randy Chen, Madhu Cherukury, Diane D.-S. Tang-Liu, Devin F. Welty, Yanbin Liang, David F. Woodward, Michael E. Garst, Darius M. Babusis, June Chen, Robert M. Burk, Larry A. Wheeler, A.M. Bogardus, and Daniel W. Gil
- Subjects
Agonist ,Colon ,medicine.drug_class ,Inositol Phosphates ,Receptors, Prostaglandin ,Prostaglandin ,Stimulation ,In Vitro Techniques ,Pharmacology ,Dinoprost ,Eye ,Mice ,chemistry.chemical_compound ,Genes, Reporter ,Ileum ,medicine ,Animals ,Humans ,Distribution (pharmacology) ,Calcium Signaling ,Gastric Fundus ,Luciferases ,Receptor ,Intraocular Pressure ,CATS ,Bimatoprost ,Chemistry ,Cloprostenol ,Glaucoma ,Muscle, Smooth ,Metabolism ,Amides ,Lipids ,Rats ,Cats ,Molecular Medicine ,Female ,Gerbillinae ,Muscle Contraction ,medicine.drug - Abstract
Replacement of the carboxylic acid group of prostaglandin (PG) F(2alpha) with a nonacidic moiety, such as hydroxyl, methoxy, or amido, results in compounds with unique pharmacology. Bimatoprost (AGN 192024) is also a pharmacologically novel PGF(2alpha) analog, where the carboxylic acid is replaced by a neutral ethylamide substituent. Bimatoprost potently contracted the feline lung parenchymal preparation (EC(50) value of 35-55 nM) but exhibited no meaningful activity in a variety of PG-sensitive tissue and cell preparations. Its activity seemed unrelated to FP receptor stimulation according to the following evidence. 1) Bimatoprost exhibited no meaningful activity in tissues and cells containing functional FP receptors. 2) Bimatoprost activity in the cat lung parenchyma is not species-specific because its potent activity in this preparation could not be reproduced in cells stably expressing the feline FP receptor. 3) Radioligand binding studies using feline and human recombinant FP receptors exhibited minimal competition versus [(3)H]17-phenyl PGF(2a) for Bimatoprost. 4) Bimatoprost pretreatment did not attenuate PGF(2alpha)-induced Ca(2+) signals in Swiss 3T3 cells. 5) Regional differences were apparent for Bimatoprost but not FP agonist effects in the cat lung. Bimatoprost reduced intraocular pressure in ocular normotensive and hypertensive monkeys over a 0.001 to 0.1% dose range. A single-dose and multiple-dose ocular distribution/metabolism studies using [(3)H]Bimatoprost (0.1%) were performed. Within the globe, bimatoprost concentrations were 10- to 100-fold higher in anterior segment tissues compared with the aqueous humor. Bimatoprost was overwhelmingly the predominant molecular species identified at all time points in ocular tissues, indicating that the intact molecule reduces intraocular pressure.
- Published
- 2003
11. Cellular and Hormonal Regulation of Pigmentation in Human Ocular Melanocytes
- Author
-
R. A. Dawson, Sheila MacNeil, M. Wagner, John W. Haycock, Manar Moustafa, L. Smith-Thomas, David F. Woodward, Achim H.-P. Krauss, and Chariklia Balafa
- Subjects
medicine.medical_specialty ,Mesoderm ,Stromal cell ,Clinical Biochemistry ,Cell Biology ,Plant Science ,Melanocyte ,Biology ,Epithelium ,In vitro ,Cell biology ,Endocrinology ,medicine.anatomical_structure ,Internal medicine ,medicine ,Immunohistochemistry ,sense organs ,Receptor ,Agronomy and Crop Science ,Developmental Biology ,Hormone - Abstract
The purpose of this study was to examine some of the factors that may be relevant to regulating pigmentation in the human eye, specifically whether choroidal and iridial melanocytes are sensitive to regulation by epithelial and stromal cells and alpha-melanocyte stimulating hormone (alpha-MSH). Human choroidal and iridial melanocytes were established in culture and co-cultured with epithelial cells and stromal cells derived both from skin and from eye in order to determine their influence on choroidal and iridial melanocyte dopa oxidase activity. In all cases, co-culture of melanocytes with either epithelial cells or fibroblasts led to an increase in dopa oxidase activity during 5 days of co-culture. The extent of the increase ranged from 60% (non-significant) to as much as 185% when both fibroblasts and keratinocytes were present. The optimal ratio of fibroblasts to melanocytes was 1:10 (for dermal fibroblasts) or 1:2 (for iridial fibroblasts) and 1:1 for all epithelial cells to melanocytes. Both choroidal (three out of three cultures) and iridial (two out of three cultures) melanocytes showed increases in dopa oxidase activity to alpha-MSH when cultured in Green's media but the same cells cultured in MCDB153 were unresponsive to alpha-MSH. These in vitro studies suggest that ocular melanocytes have the capacity to be influenced by adjacent epithelial and stromal cells with respect to pigmentation.
- Published
- 2001
12. Delayed Reversal of Shape Change in Cells Expressing FPB Prostanoid Receptors
- Author
-
John W. Regan, Charles E. Protzman, Hiromichi Fujino, Achim H.-P. Krauss, Dinesh Srinivasan, Kristen L. Pierce, and David F. Woodward
- Subjects
Gene isoform ,Agonist ,medicine.medical_specialty ,medicine.drug_class ,Tyrosine phosphorylation ,Cell Biology ,Biology ,Biochemistry ,Cell biology ,Dephosphorylation ,Focal adhesion ,chemistry.chemical_compound ,Endocrinology ,chemistry ,Cell culture ,Internal medicine ,medicine ,Receptor ,Molecular Biology ,Actin - Abstract
Prostaglandin F(2 alpha) (PGF(2 alpha)) receptors are G-protein-coupled receptors consisting of two alternative mRNA splice variants, named FP(A) and FP(B). As compared with the FP(A) isoform, the FP(B) isoform lacks the last 46 amino acids of the carboxyl terminus and, therefore, represents a truncated version of the FP(A). We recently found (Pierce, K. L., Fujino, H., Srinivasan, D., and Regan, J. W. (1999) J. Biol. Chem. 274, 35944-35949) that stimulation of both isoforms with PGF(2 alpha) leads to activation of a Rho signaling pathway, resulting in tyrosine phosphorylation of p125 focal adhesion kinase, formation of actin stress fibers, and cell rounding. Although the activation of Rho and subsequent cell rounding occur at a similar rate for both isoforms, we now report that following the removal of PGF(2 alpha) the reversal of cell rounding is much slower for cells expressing the FP(B) isoform as compared with the FP(A) isoform. Thus, in HEK-293 cells that stably express the FP(A) isoform, the reversal of cell rounding appears to be complete after 1 h, whereas for FP(B)-expressing cells there is essentially no reversal even after 2 h. Similarly, the disappearance of stress fibers and dephosphorylation of p125 focal adhesion kinase following removal of agonist are much slower in FP(B)-expressing cells than in FP(A)-expressing cells. The mechanism of this differential reversal appears to involve a difference in receptor resensitization following the removal of agonist. Based upon whole cell radioligand binding, agonist-induced stimulation of inositol phosphate formation, and mobilization of intracellular Ca(2+), the FP(B) isoform resensitizes more slowly than the FP(A) isoform. These findings suggest that the carboxyl terminus of the FP(A) is critical for resensitization and that the slower resensitization of the FP(B) isoform leads to prolonged signaling. This differential signaling distinguishes the FP(A) and FP(B) receptor isoforms and could be important toward understanding the physiological actions of PGF(2 alpha).
- Published
- 2000
13. Replacement of the carboxylic acid group of prostaglandin F2αwith a hydroxyl or methoxy substituent provides biologically unique compounds
- Author
-
Achim H.-P. Krauss, Charles E. Protzman, Licheng Shi, R. M. Burk, R. Chen, Steven W. Andrews, George Sachs, H. T. T. Dinh, Heather A. Krauss, Karen M. Kedzie, A.M. Bogardus, L. J. Kaplan, Michael B. Roof, M. E. Garst, Ming Fai Chan, Larry A. Wheeler, R. A. Ross, John W. Regan, Todd S. Gac, June Chen, Kristen L. Pierce, D.F. Woodward, and D. W. Gil
- Subjects
Pharmacology ,Prostaglandins F ,Agonist ,endocrine system ,medicine.medical_specialty ,education.field_of_study ,medicine.drug_class ,medicine.medical_treatment ,Population ,Prostaglandin ,Biological activity ,respiratory system ,chemistry.chemical_compound ,Endocrinology ,chemistry ,Internal medicine ,cardiovascular system ,medicine ,lipids (amino acids, peptides, and proteins) ,Prostaglandin D2 ,education ,Receptor ,hormones, hormone substitutes, and hormone antagonists ,Prostaglandin E - Abstract
Replacement of the carboxylic acid group of PGF(2alpha) with the non-acidic substituents hydroxyl (-OH) or methoxy (-OCH(3)) resulted in an unexpected activity profile. Although PGF(2alpha) 1-OH and PGF(2alpha) 1-OCH(3) exhibited potent contractile effects similar to 17-phenyl PGF(2alpha) in the cat lung parenchymal preparation, they were approximately 1000 times less potent than 17-phenyl PGF(2alpha) in stimulating recombinant feline and human FP receptors. In human dermal fibroblasts and Swiss 3T3 cells PGF(2alpha) 1-OH and PGF(2alpha) 1-OCH(3) produced no Ca(2+) signal until a 1 microM concentration was exceeded. Pretreatment of Swiss 3T3 cells with either 1 microM PGF(2alpha) 1-OH or PGF(2alpha) 1-OCH(3) did not attenuate Ca(2+) signal responses produced by PGF(2alpha) or fluprostenol. In the rat uterus, PGF(2alpha) 1-OH was about two orders of magnitude less potent than 17-phenyl PGF(2alpha) whereas PGF(2alpha) 1-OCH(3) produced only a minimal effect. Radioligand binding studies on cat lung parenchymal plasma membrane preparations suggested that the cat lung parenchyma does not contain a homogeneous population of receptors that equally respond to PGF(2alpha)1-OH, PGF(2alpha)1-OCH(3), and classical FP receptor agonists. Studies on smooth muscle preparations and cells containing DP, EP(1), EP(2), EP(3), EP(4), IP, and TP receptors indicated that the activity of PGF(2alpha) 1-OH and PGF(2alpha) 1-OCH(3) could not be ascribed to interaction with these receptors. The potent effects of PGF(2alpha) 1-OH and PGF(2alpha) 1-OCH(3) on the cat lung parenchyma are difficult to describe in terms of interaction with the FP or any other known prostanoid receptor.
- Published
- 2000
14. Synthesis of a novel series of 3-oxo-2,4-dioxobicyclo[3.2.1]octanes: additional evidence for two thromboxane receptor subtypes
- Author
-
Achim H.-P. Krauss, Todd S. Gac, Robert M. Burk, Linda L. Gibson, Charles E. Protzman, David F. Woodward, and Michael E. Garst
- Subjects
Vascular smooth muscle ,Platelet aggregation ,Chemistry ,Thromboxane ,Stereochemistry ,Organic Chemistry ,Clinical Biochemistry ,Pharmaceutical Science ,Stimulation ,Biological activity ,Biochemistry ,Thromboxane receptor ,Drug Discovery ,Molecular Medicine ,Receptor ,Molecular Biology - Abstract
A series of 3-oxo-2,4-dioxobicyclo[3.2.1]octanes (1–4) was synthesized and identified as potent thromboxane (TXA2) receptor agonists. Replacement of the terminal -COOH group resulted in an unexpected change in biological activity: platelet aggregation, which typically occurs in response to TP-receptor stimulation, did not occur although potent contractile properties on vascular smooth muscle were retained.
- Published
- 1994
15. Determination of leukotriene effects on human neutrophil chemotaxis in vitro by differential assessment of cell motility and polarity
- Author
-
Achim H.-P. Krauss, David F. Woodward, C.S. Spada, and A.L. Nieves
- Subjects
Microscopy ,Leukotriene ,Leukotriene D4 ,Neutrophils ,Leukotriene B4 ,Neutrophile ,Immunology ,Motility ,Chemotaxis ,Cell Biology ,In Vitro Techniques ,Biology ,In vitro ,Cell biology ,Chemotaxis, Leukocyte ,Kinetics ,chemistry.chemical_compound ,Biochemistry ,chemistry ,Cell polarity ,Humans ,Immunology and Allergy ,lipids (amino acids, peptides, and proteins) - Abstract
The effects of leukotriene (LT) B4 and D4 on the motility of human peripheral blood neutrophils were investigated employing a novel analytical method. Using the under-agarose technique, migration distance and vectorial orientation of neutrophils in response to selected LT concentrations were determined with the aid of digital image processing. Neutrophil polarization induced by a chemotactic gradient was very apparent even at fields taken adjacent to the cell seeding well where little directional cell motility had occurred. Thus, cell polarization appeared to be the earliest response to chemoattractive LTs. Cell motility occurred in a dose-dependent manner to LTB4 according to determination of the leading edge. LTD4 produced similar effects on neutrophil polarization and motility, but these occurred only at very high concentrations. These data support the view that vectorial orientation is a prerequisite for directional migration of cells and it is also feasible that these are separately regulated events. Furthermore, our studies confirm that LTB4 and, to a much lesser extent, LTD4 are chemotactic for human peripheral blood neutrophils. J. Leukoc. Biol. 55: 201–208; 1994.
- Published
- 1994
16. Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2α agonist, in preclinical models
- Author
-
Ennio Ongini, Carol B. Toris, Francesco Impagnatiello, David Gale, Valentina Borghi, Ganesh Prasanna, Wesley K. M. Chong, Samantha Carreiro, Valerio Chiroli, and Achim H.-P. Krauss
- Subjects
Male ,Intraocular pressure ,genetic structures ,Administration, Topical ,Drug Evaluation, Preclinical ,Ocular hypertension ,Glaucoma ,Prostaglandin ,Iris ,Pharmacology ,Dinoprost ,Nitric Oxide ,Nitric oxide ,Cell Line ,Aqueous Humor ,Cellular and Molecular Neuroscience ,chemistry.chemical_compound ,Tonometry, Ocular ,Ciliary body ,Dogs ,medicine ,Animals ,Nitric Oxide Donors ,Latanoprost ,Cyclic GMP ,Antihypertensive Agents ,Intraocular Pressure ,Ciliary Body ,medicine.disease ,eye diseases ,Sensory Systems ,Hypertonic saline ,Rats ,Ophthalmology ,Disease Models, Animal ,Macaca fascicularis ,medicine.anatomical_structure ,chemistry ,Guanylate Cyclase ,Anesthesia ,Prostaglandins F, Synthetic ,Female ,Ocular Hypertension ,sense organs ,Rabbits - Abstract
The aim of the study was to investigate the ocular hypotensive activity of a nitric oxide (NO)-donating latanoprost, BOL-303259-X, following topical administration. The effect of BOL-303259-X (also known as NCX 116 and PF-3187207) on intraocular pressure (IOP) was investigated in monkeys with laser-induced ocular hypertension, dogs with naturally-occurring glaucoma and rabbits with saline-induced ocular hypertension. Latanoprost was used as reference drug. NO, downstream effector cGMP, and latanoprost acid were determined in ocular tissues following BOL-303259-X administration as an index of prostaglandin and NO-mediated activities. In primates, a maximum decrease in IOP of 31% and 35% relative to baseline was achieved with BOL-303259-X at doses of 0.036% (9 μg) and 0.12% (36 μg), respectively. In comparison, latanoprost elicited a greater response than vehicle only at 0.1% (30 μg) with a peak effect of 26%. In glaucomatous dogs, IOP decreased from baseline by 44% and 10% following BOL-303259-X (0.036%) and vehicle, respectively. Latanoprost (0.030%) lowered IOP by 27% and vehicle by 9%. Intravitreal injection of hypertonic saline in rabbits increased IOP transiently. Latanoprost did not modulate this response, whereas BOL-303259-X (0.036%) significantly blunted the hypertensive phase. Following BOL-303259-X treatment, latanoprost acid was significantly elevated in rabbit and primate cornea, iris/ciliary body and aqueous humor as was cGMP in aqueous humor. BOL-303259-X lowered IOP more effectively than latanoprost presumably as a consequence of a contribution by NO in addition to its prostaglandin activity. The compound is now in clinical development for the treatment of glaucoma and ocular hypertension.
- Published
- 2010
17. Effect of PF-04217329 a prodrug of a selective prostaglandin EP(2) agonist on intraocular pressure in preclinical models of glaucoma
- Author
-
M.R. Niesman, David Gale, Hovhannes J. Gukasyan, Achim H.-P. Krauss, Jay H. Fortner, Jennifer Lafontaine, Husam S. Younis, Soisurin Sartnurak, Ganesh Prasanna, Carol B. Toris, Dac M. Dinh, Scott Anderson, Samantha Carreiro, Cathie Xiang, Chau Almaden, and Peter A. Wells
- Subjects
Agonist ,Male ,Intraocular pressure ,genetic structures ,Open angle glaucoma ,medicine.drug_class ,medicine.medical_treatment ,Prostaglandin E2 receptor ,Administration, Topical ,Drug Evaluation, Preclinical ,Glaucoma ,Prostaglandin ,Biological Availability ,Iris ,Pharmacology ,Acetates ,Aqueous Humor ,Cornea ,Cellular and Molecular Neuroscience ,chemistry.chemical_compound ,Tonometry, Ocular ,Dogs ,medicine ,Cyclic AMP ,Animals ,Humans ,Prodrugs ,Antihypertensive Agents ,Intraocular Pressure ,Sulfonamides ,Ciliary Body ,Prodrug ,Receptors, Prostaglandin E, EP2 Subtype ,medicine.disease ,eye diseases ,Sensory Systems ,Ophthalmology ,Disease Models, Animal ,Macaca fascicularis ,chemistry ,Calcium ,sense organs ,Rabbits ,Ophthalmic Solutions ,Glaucoma, Open-Angle ,Prostaglandin E - Abstract
Better control of intraocular pressure (IOP) is the most effective way to preserve visual field function in glaucomatous patients. While prostaglandin FP analogs are leading the therapeutic intervention for glaucoma, new target classes also are being identified with new lead compounds being developed for IOP reduction. One target class currently being investigated includes the prostaglandin EP receptor agonists. Recently PF-04217329 (Taprenepag isopropyl), a prodrug of CP-544326 (active acid metabolite), a potent and selective EP(2) receptor agonist, was successfully evaluated for its ocular hypotensive activity in a clinical study involving patients with primary open angle glaucoma. In the current manuscript, the preclinical attributes of CP-544326 and PF-0421329 have been described. CP-544326 was found to be a potent and selective EP(2) agonist (IC(50) = 10 nM; EC(50) = 2.8 nM) whose corneal permeability and ocular bioavailability were significantly increased when the compound was dosed as the isopropyl ester prodrug, PF-04217329. Topical ocular dosing of PF-04217329 was well tolerated in preclinical species and caused an elevation of cAMP in aqueous humor/iris-ciliary body indicative of in vivo EP(2) target receptor activation. Topical ocular dosing of PF-04217329 resulted in ocular exposure of CP-544326 at levels greater than the EC(50) for the EP(2) receptor. PF-04217329 when dosed once daily caused between 30 and 50% IOP reduction in single day studies in normotensive Dutch-belted rabbits, normotensive dogs, and laser-induced ocular hypertensive cynomolgus monkeys and 20-40% IOP reduction in multiple day studies compared to vehicle-dosed eyes. IOP reduction was sustained from 6 h through 24 h following a single topical dose. In conclusion, preclinical data generated thus far appear to support the clinical development of PF-04217329 as a novel compound for the treatment of glaucoma.
- Published
- 2010
18. ChemInform Abstract: Synthesis of a Novel Series of 3-Oxo-2,4-dioxabicyclo(3.2.1)octanes: Additional Evidence for Two Thromboxane Receptor Subtypes
- Author
-
D.F. Woodward, Achim H.-P. Krauss, R. M. Burk, Linda L. Gibson, Todd S. Gac, M. E. Garst, and Charles E. Protzman
- Subjects
Thromboxane receptor ,Stereochemistry ,Chemistry ,General Medicine ,Hormone - Published
- 2010
19. Bimatoprost effects on aqueous humor dynamics in monkeys
- Author
-
Achim H.-P. Krauss, Siv F. E. Nilsson, and David F. Woodward
- Subjects
Intraocular pressure ,medicine.medical_specialty ,Article Subject ,Bimatoprost ,genetic structures ,business.industry ,Aqueous flow ,Uveoscleral outflow ,MEDICINE ,Aqueous humor flow ,Aqueous humor ,eye diseases ,Ophthalmology ,MEDICIN ,lcsh:Ophthalmology ,lcsh:RE1-994 ,Medicine ,Perfusion method ,Outflow ,sense organs ,business ,medicine.drug ,Research Article - Abstract
The effects of bimatoprost on aqueous humor dynamics were quantified in monkey eyes. Uveoscleral outflow was measured by the anterior chamber perfusion method, using FITC-dextran. Total outflow facility was determined by the two-level constant pressure method. Aqueous flow was measured with a scanning ocular fluorophotometer. Uveoscleral outflow was 0 . 9 6 ± 0 . 1 9 𝜇 L m i n − 1 in vehicle-treated eyes and 1 . 3 7 ± 0 . 2 7 𝜇 L m i n − 1 ( 𝑛 = 6 ; 𝑃 < . 0 5 ) in eyes that received bimatoprost 0.01% b.i.d. × 5 days. Bimatoprost had no effect on total outflow facility, which was 0 . 4 2 ± 0 . 0 5 𝜇 L m i n − 1 at baseline and 0 . 4 2 ± 0 . 0 4 𝜇 L m i n − 1 after bimatoprost treatment. Bimatoprost had no significant effect on aqueous humor flow. This study demonstrates that bimatoprost increases uveoscleral outflow but not total outflow facility or aqueous humor flow, indicating that it lowers intraocular pressure in ocular normotensive monkeys by a mechanism that exclusively involves uveoscleral outflow.
- Published
- 2010
20. Correlation of in vitro and in vivo kinetics of nitric oxide donors in ocular tissues
- Author
-
Hovhannes J. Gukasyan, Achim H.-P. Krauss, Samantha Carreiro, Ganesh Prasanna, and Scott Anderson
- Subjects
Nitroprusside ,Intraocular pressure ,genetic structures ,Stereochemistry ,Administration, Topical ,Vasodilator Agents ,Pharmacology ,In Vitro Techniques ,S-Nitroso-N-Acetylpenicillamine ,Nitric Oxide ,Ciliary Arteries ,Muscle, Smooth, Vascular ,Nitric oxide ,chemistry.chemical_compound ,Ciliary body ,In vivo ,medicine ,Animals ,Humans ,Pharmacology (medical) ,Nitric Oxide Donors ,Cyclic GMP ,Intraocular Pressure ,Snap ,Blood flow ,eye diseases ,In vitro ,Ophthalmology ,medicine.anatomical_structure ,chemistry ,Female ,sense organs ,Sodium nitroprusside ,Rabbits ,medicine.drug - Abstract
In the eye, nitric oxide (NO) is involved in the regulation of intraocular pressure (IOP) and ocular blood flow. The main purpose of this study was to measure the kinetics of NO release from NO donors in ocular cells and tissues using in vivo and in vitro models and demonstrate the link between the kinetics of NO release with the functional effect, IOP. Nitric oxide release was measured in human ocular cells using a fluorescent dye, diaminofluorescein (DAF), following treatment with short-acting sodium nitroprusside (SNP) and longer-acting S-nitroso-N-acetylpenicillamine (SNAP) NO donors. Both SNP and SNAP were also administered topically to rabbits; IOP was measured and levels of NO and cGMP were assessed as biomarkers over a time course in the aqueous humor (AH) and iris/ciliary body (ICB). Time- and concentration-dependent increases in NO level were produced by SNP and SNAP in human ocular cells. Both NO and cGMP levels appeared to be elevated following treatment with the aforementioned NO donors in rabbit ocular tissues. Transient IOP lowering was accompanied with these biochemical estimations in rabbits, with time of maximal effect being shifted to the right for longer-acting SNAP as compared with short-acting SNP. In vitro and in vivo NO/cGMP assay results displayed a correlation between short- and longer-acting NO donors, discriminating their respective temporal actions in the eye. Due to their translatability, the in vitro DAF assay and in vivo NO fluorometric assay can therefore be potentially useful in screening novel NO donors with different temporal/kinetic profiles.
- Published
- 2009
21. Ocular pharmacokinetics and hypotensive activity of PF-04475270, an EP4 prostaglandin agonist in preclinical models
- Author
-
Scott Anderson, Cathie Xiang, Chau Almaden, Samantha Carreiro, Jay H. Fortner, Sajiv Krishnan Nair, Jennifer Lafontaine, M.R. Niesman, Hovhannes J. Gukasyan, Eric Zhang, Grace Wu, Rui Eugene Yuanjin, Ganesh Prasanna, Peter A. Wells, Achim H.-P. Krauss, and Soisurin Sartnurak
- Subjects
Agonist ,Intraocular pressure ,genetic structures ,medicine.drug_class ,Administration, Topical ,Ocular hypertension ,Glaucoma ,Biological Availability ,Hyperemia ,CHO Cells ,Thiophenes ,Pharmacology ,Eye ,Transfection ,Permeability ,Cellular and Molecular Neuroscience ,Ciliary body ,Cricetulus ,Dogs ,Pharmacokinetics ,Cornea ,Cricetinae ,Cyclic AMP ,Medicine ,Animals ,Humans ,Receptors, Prostaglandin E ,Prodrugs ,Intraocular Pressure ,Dose-Response Relationship, Drug ,business.industry ,Hydrolysis ,Prodrug ,medicine.disease ,eye diseases ,Sensory Systems ,Pyrrolidinones ,Ophthalmology ,medicine.anatomical_structure ,Models, Animal ,sense organs ,Rabbits ,Ophthalmic Solutions ,business ,Receptors, Prostaglandin E, EP4 Subtype - Abstract
Prostaglandins are widely used to lower intraocular pressure (IOP) as part of the treatment regimen for glaucoma. While FP and EP2 agonists are known to lower IOP, we investigated the ocular hypotensive activity and ocular drug distribution of PF-04475270, a novel EP4 agonist following topical administration in normotensive Beagle dogs. PF-04475270 is a prodrug of CP-734432, which stimulated cAMP formation in HEK293 cells expressing EP4 receptor and beta-lactamase activity in human EP4 expressing CHO cells transfected with a cAMP response element (CRE) with an EC(50) of 1 nM. Prodrug conversion and transcorneal permeability were assessed in rabbit corneal homogenates and a human corneal epithelial cell (cHCE) model. The compound underwent rapid hydrolysis to CP-734432 in corneal homogenates, and exhibited good permeability in the cHCE model. The descending order of ocular exposure to CP-734432 after topical dosing of PF-04475270 in dogs was as follows: cornea > aqueous humor >or= iris/ciliary body. When administered q.d., PF-04475270 lowered IOP effectively in the dog IOP model both after single and multiple days of dosing. A maximum decrease in IOP with PF-04475270 was between 30 and 45% at 24h post-dose relative to that observed with vehicle. In conclusion, PF-04475270 is a novel ocular hypotensive compound which is bioavailable following topical dosing, effectively lowering IOP in dogs. EP4 agonists could be considered as potential targets for lowering IOP for the treatment of glaucoma and ocular hypertension.
- Published
- 2009
22. Improvement of Outcome Measures of Dry Eye by a Novel Integrin Antagonist in the Murine Desiccating Stress Model
- Author
-
Johanna Tukler-Henriksson, Cintia S. de Paiva, Achim H.-P. Krauss, Flavia S. A. Pelegrino, Rosa M. Corrales, and Stephen C. Pflugfelder
- Subjects
Administration, Topical ,Integrin alpha4 ,Phenylalanine ,Integrin ,Anti-Inflammatory Agents ,Vascular Cell Adhesion Molecule-1 ,Integrin alpha4beta1 ,CD49d ,Collagen receptor ,Cornea ,Mice ,Piperidines ,Cell Adhesion ,Leukocytes ,Animals ,Organic Chemicals ,Cells, Cultured ,Integrin alpha Chains ,biology ,Cell adhesion molecule ,CD29 ,Dendritic Cells ,Flow Cytometry ,eye diseases ,Mice, Inbred C57BL ,Disease Models, Animal ,Integrin alpha M ,Immunology ,biology.protein ,Eye disorder ,Dry Eye Syndromes ,Female ,Biomarkers - Abstract
Dry eye disease (DED) is one of the most common and discomforting eye disorders. It has been defined as a multifactorial ocular surface disease more prevalent in women and the elderly. Dry eye disease is associated with symptoms of discomfort, visual disturbance, tear film instability, and inflammation of the ocular surface leading to potential damage to the ocular surface tissues.1 The proinflammatory milieu is characterized by increased levels of cytokines and chemokines in the tear film, cornea, and conjunctiva, and increased autoreactive T-cell infiltration of the conjunctival epithelium and sometimes lacrimal gland2–4; reviewed by Stern et al.5,6 Alteration of the tear film composition (mucins, lipids, proteins) and decreased volume lead to tear film abnormalities that contribute to the disease cycle. Subjecting mice to a controlled environment of desiccating stress results in ocular surface pathology reminiscent of human DED in patients in many respects.3,7–9 As of today, this model represents the best characterized animal model to study DED. Integrins are heterodimeric glycoproteins consisting of one α- and one β-subunit. Expressed on the cell surface of leukocytes, integrins have a role in their recruitment to sites of inflammation. The association of a specific α- and β-subunit determines the ligand specificity of the integrin. The α4 integrin subunit (CD49d) is a constituent of Very Late Antigen-4 (VLA-4, integrin a4b1, CD49d/CD29), and α4β7 (CD49d/CD103). In the case of integrin α4β1 the corresponding ligands are the immunoglobulin superfamily adhesion molecule vascular cell adhesion molecule 1 (VCAM-1) on vascular endothelial cells and the extracellular matrix glycoprotein fibronectin, which are responsible for the homing, trafficking, differentiation, priming, activation, and survival of integrin α4β1 expressing cells. Integrin α4β1 is expressed on lymphocytes, monocytes, macrophages, NK cells, and eosinophils. Integrin α4β7 and its corresponding ligand Mucosal Addressin Cell Adhesion Molecule-1 (MAdCAM) selectively regulate leukocyte trafficking to the gut and consequently are unlikely to be involved in the effects described herein. Natalizumab, an antibody directed against the α4 integrin subunit, has been shown to profoundly inhibit inflammation and improve clinical outcomes in multiple sclerosis10 and Crohn's disease,11 which also are T-cell–mediated diseases. Lifitegrast, a small molecule antagonist, directed against a different adhesion molecule (LFA-1, integrin αLβ2), has been shown to reduce corneal staining and improve symptoms when delivered topically to dry eye patients.12 Furthermore, a specific antagonist to integrin α4β1, BIO-8809, had been shown to decrease corneal fluorescein staining, conjunctival T-cell infiltrates, and TNFα expression in cornea and conjunctiva in a murine dry eye model.13 Taken together these considerations provided a rationale for further exploring the blockade of integrin α4 in an animal model of DED. In the current study, we tested the hypothesis using {"type":"entrez-nucleotide","attrs":{"text":"GW559090","term_id":"289141609","term_text":"GW559090"}}GW559090, a potent integrin α4 antagonist that previously had been clinically investigated in asthma patients by the oral inhalation route.14
- Published
- 2015
23. The prostanoid EP2 receptor agonist butaprost increases uveoscleral outflow in the cynomolgus monkey
- Author
-
Elke Lütjen-Drecoll, Enken Drecoll, Alexander B. Kharlamb, Achim H.-P. Krauss, Siv F. E. Nilsson, David F. Woodward, Teresa Guerra, Carol B. Toris, and A.L. Nieves
- Subjects
Agonist ,Prostaglandins E, Synthetic ,Intraocular pressure ,medicine.medical_specialty ,genetic structures ,medicine.drug_class ,Administration, Topical ,Ocular hypertension ,Biology ,Fluorophotometry ,Aqueous Humor ,chemistry.chemical_compound ,Trabecular Meshwork ,Ophthalmology ,medicine ,Animals ,Receptors, Prostaglandin E ,Alprostadil ,Uvea ,Intraocular Pressure ,Ciliary Body ,Prostanoid ,Dextrans ,Muscle, Smooth ,Receptors, Prostaglandin E, EP2 Subtype ,medicine.disease ,eye diseases ,Disease Models, Animal ,Macaca fascicularis ,medicine.anatomical_structure ,Ciliary muscle ,chemistry ,Anesthesia ,Ocular Hypertension ,sense organs ,Trabecular meshwork ,Perfusion ,Fluorescein-5-isothiocyanate ,Sclera - Abstract
PURPOSE. To investigate the ocular hypotensive effect of the prostanoid EP2 receptor agonist butaprost and to establish its mechanism of action. METHODS. All experiments were performed in cynomolgus monkeys after topical application of butaprost (0.1%). The effects of butaprost on aqueous humor flow were determined by fluorophotometry. Total outflow facility was measured by the two-level, constant-pressure perfusion method, and uveoscleral outflow was determined by perfusion of FITC-labeled dextran through the anterior chamber. Effects on ocular morphology were studied after tissue fixation with transcardial perfusion by paraformaldehyde and immersion fixation of the globe, in animals subjected to long-term treatment with butaprost. Conscious ocular normotensive monkeys and monkeys with unilateral ocular hypertension were used for intraocular pressure (IOP) studies. RESULTS. Butaprost had no significant effect on aqueous humor flow or total outflow facility in ocular normotensive monkeys. Uveoscleral outflow was significantly higher in the butaprost treated eyes than in vehicle treated eyes, 1.03 ± 0.20 vs. 0.53 ± 0.18 μL · min-1. After a 1-year treatment with butaprost, the morphology of the ciliary muscle was changed, showing increased spaces between ciliary muscle bundles and the apparent formation of new outflow channels. In many instances, changes were observed in the trabecular meshwork as well. Butaprost, in a single 0.1% dose, decreased IOP significantly in ocular normotensive monkeys and reduced IOP in laser-induced glaucomatous monkey eyes to the same level as that in the ocular normotensive contralateral eyes. CONCLUSIONS. The prostanoid EP2 receptor agonist butaprost appears to lower IOP by increasing uveoscleral outflow, according to both physiological and morphologic findings. Although the prostanoid EP2 receptor is structurally and functionally distinct from the FP receptor, the effects of EP2 and FP receptor stimulation on aqueous humor outflow are similar. Copyright © Association for Research in Vision and Ophthalmology.
- Published
- 2006
24. Aqueous Humor Outflow: What Do We Know? Where Will It Lead Us?
- Author
-
Makoto Aihara, Thomas F. Freddo, Michael P. Fautsch, Casey Kopczynski, Craig E. Crosson, James D. Lindsey, Darrell WuDunn, Paul L. Kaufman, G. Prasanna, Abbot F. Clark, John W. Grunden, Paul A. Knepper, David L. Epstein, David C. Zawieja, Christopher A. Paterson, Ernst R. Tamm, Elizabeth E. Kim, Paul Russell, Alan W. Stitt, Douglas H. Johnson, Douglas J. Rhee, Ted S. Acott, Peter F. Davies, Beatrice Y.J.T. Yue, C. Ross Ethier, Terete Borras, Achim H.-P. Krauss, Sanjoy K. Bhattacharya, Jonathan G Crowston, Eveline E. Schneeberger, Donna M. Peters, Dontscho Kerjaschki, C. Bosworth, P. Vasantha Rao, Noorjahan Panjwani, Simon W. M. John, Pedro Gonzalez, Carol B. Toris, Andy Whitlock, Mortimer M. Civan, Paul Bornstein, Benjamin Geiger, Sayon Roy, Mark Johnson, Daniel Stamer, Robert N. Weinreb, Elke Lütjen-Drecoll, James B. Mitchell, Carl B. Camras, and Haiyan Gong
- Subjects
Aqueous outflow ,business.industry ,Uveoscleral outflow ,Library science ,Northern ireland ,Article ,Oxidative damage ,Medicine ,Optometry ,Club ,Session (computer science) ,General hospital ,business ,Aqueous humor outflow - Abstract
The second annual ARVO/Pfizer Ophthalmic Research Institute conference was held Friday and Saturday, April 28 and 29, 2006, at the Fort Lauderdale Grande Hotel and Yacht Club, Fort Lauderdale, Florida. The conference, funded by The ARVO Foundation for Eye Research through a grant from Pfizer Ophthalmics, provided an opportunity to gather experts from within and outside ophthalmology to develop strategies to improve research and clinical care in areas of ophthalmology related to preventable vision loss and blindness. This year’s conference focused on aqueous humor outflow. A working group of 31 researchers on aqueous outflow, 8 scientists working on interests other than aqueous humor outflow but with expertise in areas relevant to the field, and 11 observers from ARVO, Pfizer, and clinical and basic ophthalmic research convened on April 28, 2006, to evaluate the current understanding of the aqueous humor outflow pathway. The goals were to compare similarities between ocular aqueous humor outflow and fluid flow in other tissues of the body, to critique conventional ideas, to identify the most important scientific questions, and to discuss strategies to answer these questions. The meeting format emphasized discussion and concentrated on questions within four general areas of outflow research: Session I: Conventional Outflow: Cell Function in the Aqueous Humor Outflow Pathway Session II: Conventional Outflow: Role of the Extracellular Matrix Session III: Uveoscleral Outflow: The Other Pathway Session IV: Normal Versus Primary Open Angle Glaucoma (POAG): What Is the Cause of Elevated Pressure? Each session began with a 10-minute overview by an outflow researcher followed by a 30-minute talk by one of the outside experts. Parallels between their fields of expertise and the eye were included in these talks. Invited outside experts covered several areas of research, including vascular endothelial cell biology (Peter Davies, PhD, University of Pennsylvania, Philadelphia), matricellular proteins (Paul Bornstein, MD, University of Washington, Seattle), renal and lymphatic biology (Donatscho Kerjaschki, MD, University of Vienna, Austria, and David Zawiega, PhD, Texas A & M University, College Station, Texas), oxidative damage mechanisms (James Mitchell, PhD, National Institutes of Health, Bethesda, Maryland), advanced glycation end-products and aging (Alan Stitt, PhD, Queens University, Belfast, Northern Ireland), cell adhesion (Benjamin Geiger, PhD, Weizmann Institute of Science, Rehovot, Israel), and cellular tight junctions (Eveline Schneeberger, MD, Massachusetts General Hospital, Boston, Massachusetts). The remainder of each session was used to discuss questions pertinent to the main topic and provided an opportunity for attendees to voice their opinions and work together to define questions that are still unanswered. The lively discussions were successful in defining old and new ideas that are essential to a better understanding of aqueous humor outflow. This conference summary highlights the ideas discussed and introduces areas that need further exploration.
- Published
- 2006
- Full Text
- View/download PDF
25. Bimatoprost and prostaglandin F(2 alpha) selectively stimulate intracellular calcium signaling in different cat iris sphincter cells
- Author
-
David F. Woodward, Larry A. Wheeler, C.S. Spada, Achim H.-P. Krauss, Charles E. Protzman, June Chen, A.L. Nieves, David F. Scott, and George Sachs
- Subjects
medicine.medical_specialty ,Prostaglandin E2 receptor ,Alpha (ethology) ,Prostaglandin ,Iris ,Biology ,Cholinergic Agonists ,Dinoprost ,Calcium in biology ,Cellular and Molecular Neuroscience ,chemistry.chemical_compound ,Internal medicine ,medicine ,Animals ,Humans ,Calcium Signaling ,Prostaglandin receptor ,Receptor ,Cells, Cultured ,Intraocular Pressure ,Microscopy, Confocal ,Bimatoprost ,Cloprostenol ,Amides ,Lipids ,Sensory Systems ,Ophthalmology ,Endocrinology ,Mechanism of action ,chemistry ,Cats ,lipids (amino acids, peptides, and proteins) ,Calcium ,Carbachol ,medicine.symptom ,medicine.drug ,Muscle Contraction - Abstract
Bimatoprost is a synthetic analog of prostaglandin F(2 alpha) ethanolamide (prostamide F(2 alpha)), and shares a pharmacological profile consistent with that of the prostamides. Like prostaglandin F(2 alpha) carboxylic acid, bimatoprost potently lowers intraocular pressure in dogs, primates and humans. In order to distinguish its mechanism of action from prostaglandin F(2 alpha), fluorescence confocal microscopy was used to examine the effects of bimatoprost, prostaglandin F(2 alpha) and 17-phenyl prostaglandin F(2 alpha) on calcium signaling in resident cells of digested cat iris sphincter, a tissue which exhibits contractile responses to both agonists. Constant superfusion conditions obviated effective conversion of bimatoprost. Serial challenge with 100 nM bimatoprost and prostaglandin F(2 alpha) consistently evoked responses in different cells within the same tissue preparation, whereas prostaglandin F(2 alpha) and 17-phenyl prostaglandin F(2 alpha) elicited signaling responses in the same cells. Bimatoprost-sensitive cells were consistently re-stimulated with bimatoprost only, and prostaglandin F(2 alpha) sensitive cells could only be re-stimulated with prostaglandin F(2 alpha). The selective stimulation of different cells in the same cat iris sphincter preparation by bimatoprost and prostaglandin F(2 alpha), along with the complete absence of observed instances in which the same cells respond to both agonists, strongly suggests the involvement of distinct receptors for prostaglandin F(2 alpha) and bimatoprost. Further, prostaglandin F(2 alpha) but not bimatoprost potently stimulated calcium signaling in isolated human embryonic kidney cells stably transfected with the feline- and human-prostaglandin F(2 alpha) FP-receptor and in human dermal fibroblast cells, and only prostaglandin F(2 alpha) competed with radioligand binding in HEK-feFP cells. These studies provide further evidence for the existence of a bimatoprost-sensitive receptor that is distinct from any of the known prostaglandin receptor types.
- Published
- 2004
26. Prostaglandin ethanolamides (prostamides): in vitro pharmacology and metabolism
- Author
-
Filomena Fezza, T. Bisogno, Isabel Matias, V. Di Marzo, Alessia Ligresti, R. M. Burk, Yanbin Liang, Chen Li, Karen M. Kedzie, June Chen, Achim H.-P. Krauss, A.L. Nieves, Licheng Shi, David F. Woodward, L. De Petrocellis, and Charles E. Protzman
- Subjects
Polyunsaturated Alkamides ,Receptors, Drug ,Guinea Pigs ,Receptors, Prostaglandin ,TRPV1 ,Prostaglandin ,Iris ,TRPV Cation Channels ,Endogeny ,Arachidonic Acids ,Biology ,Amidohydrolases ,Cell Line ,Rats, Sprague-Dawley ,chemistry.chemical_compound ,Mice ,Fatty acid amide hydrolase ,FP and CANNABINOID RECEPTORS ,Cannabinoid Receptor Modulators ,Tumor Cells, Cultured ,Animals ,Humans ,Settore BIO/10 ,ANANDAMIDE AMIDOHYDROLASE ,Receptor ,Pharmacology ,RABBIT JUGULAR-VEIN ,Hydrolysis ,ENDOCANNABINOIDS ,Prostanoid ,BIMATOPROST ,Metabolism ,Endocannabinoid system ,Amides ,Recombinant Proteins ,Rats ,chemistry ,Biochemistry ,Ethanolamines ,Cats ,Prostaglandins ,Molecular Medicine ,lipids (amino acids, peptides, and proteins) ,Rabbits ,Jugular Veins ,Synaptosomes - Abstract
We investigated whether prostaglandin ethanolamides (prostamides) E(2), F(2alpha), and D(2) exert some of their effects by 1) activating prostanoid receptors either per se or after conversion into the corresponding prostaglandins; 2) interacting with proteins for the inactivation of the endocannabinoid N-arachidonoylethanolamide (AEA), for example fatty acid amide hydrolase (FAAH), thereby enhancing AEA endogenous levels; or 3) activating the vanilloid receptor type-1 (TRPV1). Prostamides potently stimulated cat iris contraction with potency approaching that of the corresponding prostaglandins. However, prostamides D(2), E(2), and F(2alpha) exhibited no meaningful interaction with the cat recombinant FP receptor, nor with human recombinant DP, EP(1-4), FP, IP, and TP prostanoid receptors. Prostamide F(2alpha) was also very weak or inactive in a panel of bioassays specific for the various prostanoid receptors. None of the prostamides inhibited AEA enzymatic hydrolysis by FAAH in cell homogenates, or AEA cellular uptake in intact cells. Furthermore, less than 3% of the compounds were hydrolyzed to the corresponding prostaglandins when incubated for 4 h with homogenates of rat brain, lung, or liver, and cat iris or ciliary body. Very little temperature-dependent uptake of prostamides was observed after incubation with rat brain synaptosomes or RBL-2H3 cells. We suggest that prostamides' most prominent pharmacological actions are not due to transformation into prostaglandins, activation of prostanoid receptors, enhancement of AEA levels, or gating of TRPV1 receptors, but possibly to interaction with novel receptors that seem to be functional in the cat iris.
- Published
- 2004
27. Ocular hypotensive activity of prostaglandin F2 alpha (PGF2 alpha) analogs with neutral substituents at position 1 is predicted by the isolated cat iris sphincter smooth muscle preparation but not Ca+ signalling in Swiss 3T3 cells
- Author
-
Robert M, Burk, David F, Woodward, Achim H P, Krauss, June, Chen, Charles E, Protzmann, Linda S, Williams, and Ming F, Chan
- Subjects
Mice ,Cats ,Animals ,Iris ,Muscle, Smooth ,Ocular Hypertension ,3T3 Cells ,Calcium Signaling ,Dinoprost ,Antihypertensive Agents - Published
- 2003
28. Ocular Hypotensive Activity of Prostaglandin F2α (PGF2α) Analogs with Neutral Substituents at Position 1 is Predicted by the Isolated Cat Iris Sphincter Smooth Muscle Preparation but not Ca+ Signalling in Swiss 3T3 Cells
- Author
-
Ming F. Chan, Robert M. Burk, David F. Woodward, Achim H.-P. Krauss, June Chen, Charles E. Protzmann, and Linda S. Williams
- Subjects
chemistry.chemical_classification ,medicine.medical_specialty ,Stereochemistry ,Carboxylic acid ,Prostaglandin ,Sulfonamide ,Swiss 3T3 Cells ,chemistry.chemical_compound ,medicine.anatomical_structure ,Endocrinology ,chemistry ,Internal medicine ,medicine ,Potency ,Sphincter ,Tetrazole ,Selectivity - Abstract
Typically, the C-1 carboxylic acid (CO2H) has been considered an essential pharmacophoric group for ligand binding to the FP-receptor. Historically, in drug design and development, a formal negatively charged carboxylic acid can be replaced with a group of similar pKa, such as tetrazole or an acyl sulfonamide. This change sometimes provides better selectivity and/or increased potency due to better metabolic stability. We investigated replacement of the C-1 carboxylic acid with a variety of uncharged C-1 substituents. A diverse series of Cl-analogs was synthesized and certain compounds, especially AGN-191129 (PGF2aOCH3), exhibited an apparent unique pharmacology, thus confiming the importance of the Cl-CO2H for binding to the FP-receptor.
- Published
- 2002
29. Pharmacological evidence for thromboxane receptor heterogeneity--implications for the eye
- Author
-
Todd S. Gac, Robert M. Burk, David F. Woodward, Judith Senior, Achim H.-P. Krauss, Charles E. Protzman, Farhat Abbass, Linda L. Gibson, and Kay Marshall
- Subjects
Agonist ,Blood Platelets ,medicine.medical_specialty ,Platelet Aggregation ,medicine.drug_class ,Guinea Pigs ,Receptors, Thromboxane ,Ocular Hypotension ,Biology ,Eye ,Thromboxane receptor ,Capillary Permeability ,Thromboxane A2 ,chemistry.chemical_compound ,Dogs ,In vivo ,Internal medicine ,medicine ,Animals ,Humans ,Vasoconstrictor Agents ,Pharmacology (medical) ,Platelet ,Intraocular Pressure ,Pharmacology ,Biological activity ,Muscle, Smooth ,Pupil ,Bridged Bicyclo Compounds, Heterocyclic ,In vitro ,Prostaglandin Endoperoxides, Synthetic ,Rats ,Ophthalmology ,medicine.anatomical_structure ,Endocrinology ,Hydrazines ,chemistry ,15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid ,Cats ,Fatty Acids, Unsaturated ,Chickens ,Conjunctiva ,Blood vessel ,Muscle Contraction - Abstract
The pharmacological activity of two novel thromboxane A2 (TxA2)-mimetics, AGN191976 and AGN192093, was investigated in vitro, using standard organ bath assays and human platelets, to determine potency and selectivity at various prostanoid (PG-) receptors. The effects of these compounds on intraocular pressure in Beagle dogs were then compared with U-46619, a widely employed and structurally different TP-receptor agonist. AGN191976 and AGN192093 were highly potent TP-receptor agonists in the rat aorta (EC50 of 0.32 and 1.3 nM, respectively) and human myometrium. Both compounds were approximately 10 to 50 fold more potent than U-46619. These contractile responses could be blocked with a potent TP-receptor antagonist, SQ29548. In human platelets, AGN191976 (EC50 = 16.3 nM) and U-46619 (EC50 = 538.3 nM) potently stimulated aggregation (TP-receptor mediated effect), whereas AGN192093 was a much weaker agonist (EC50 = 37.9 microM). AGN192093 was not a partial agonist in platelets, since it did not antagonize aggregation induced by AGN191976, U-46619, arachidonic acid or ADP. These results provide evidence for a subdivision of TP-receptors, and AGN192093 appears to be able to distinguish between TP-receptors in smooth muscle and platelets. In the Beagle dog eye, both AGN191976 and AGN192093 were highly potent and efficacious ocular hypotensives. Single 2.5 micrograms doses of drug decreased IOP by 11.4 (AGN191976) and 7.7 mm Hg (AGN192093) relative to the contralateral control eye. In contrast, U-46619 did not lower IOP. AGN191976, but not U-46619, increased outflow facility in these animals, which is consistent with their effects on IOP. Neither compound caused miosis which is FP-receptor mediated in the dog. These studies suggest the existence of heterogeneous populations of TP-receptors. AGN191976 and AGN192093, two novel TP-receptor agonists, appear to be useful tools for the pharmacological distinction of TP-receptor subtypes.
- Published
- 1997
30. Prostaglandin effects on the contractility of bovine trabecular meshwork and ciliary muscle
- Author
-
David F. Woodward, Michael Wiederholt, Annette Sturm, and Achim H.-P. Krauss
- Subjects
Agonist ,medicine.medical_specialty ,Carbachol ,Contraction (grammar) ,genetic structures ,medicine.drug_class ,Muscle Relaxation ,Receptors, Prostaglandin ,Prostaglandin ,Biology ,Contractility ,Cellular and Molecular Neuroscience ,chemistry.chemical_compound ,Trabecular Meshwork ,Internal medicine ,Prostaglandins, Synthetic ,medicine ,Animals ,Receptors, Prostaglandin E ,Ciliary Body ,Prostanoid ,Sensory Systems ,Ophthalmology ,Endocrinology ,medicine.anatomical_structure ,Ciliary muscle ,chemistry ,lipids (amino acids, peptides, and proteins) ,Cattle ,sense organs ,Trabecular meshwork ,medicine.drug ,Muscle Contraction - Abstract
The ocular hypotensive activity of prostaglandins (PGs) has previously been demonstrated in various species including man. The underlying mechanism of action of prostanoids other than PGF2 alpha remains contentious. Because the trabecular meshwork and ciliary muscle are believed to have a role in the regulation of aqueous humor outflow, the aim of this study was to identify the PG-receptor subtypes present in these tissues using receptor-selective agonists. Contractions of isolated strips of bovine trabecular meshwork and ciliary muscle were recorded isometrically in continuously perfused tissue chambers. Contractile activity of PGs was determined relative to a maximally effective concentration of carbachol (1 microM) as a standard agonist. The following prostanoids were employed: PGF2 alpha, 17-phenyl PGF2 alpha (FP-receptor agonists), sulprostone (EP3 > EP1-agonist), AH13205 (EP2-agonist), 11-deoxy PGE1 (non-selective EP-agonist), and U-46619 (TP-agonist). The thromboxane-mimetic U-46619 elicited a strong contraction of the trabecular meshwork with the highest concentration (1 microM) being almost twice as efficacious (186.6%) as the maximal carbachol concentration, whereas the effect on the ciliary muscle was small. The U-46619 induced trabecular meshwork contraction could be blocked with a potent and selective TP-receptor antagonist, 1 microM SQ29548, indicating the involvement of TP-receptors. The other PG-analogs studied had either no or a small but statistically significant effect. Thus, 17-phenyl PGF2 alpha (1 microM) weakly contracted the ciliary muscle (4.8%), sulprostone (1 microM) the trabecular meshwork (10.1%), 11-deoxy PGE1 (1 microM) and AH13205 (10 microM) elicited relaxations in both tissue precontracted with carbachol (1 microM). The relaxant effects were more pronounced in trabecular meshwork (15.6% for 11-deoxy PG1 and 21.4% for AH13205) than ciliary muscle (6.8 and 7.4% respectively). PGF2 alpha did not elicit a significant response in either tissue. Our studies suggest the existence of TP- and EP2-receptors in the bovine trabecular meshwork and potentially FP- and EP2-receptors in the ciliary muscle. In conclusion, thromboxane-mimetics and EP2-agonists have opposing activities on contractile elements in the meshwork and may modulate trabecular outflow in a functionally antagonistic manner. Prostanoid effects on ciliary muscle appear rather modest compared to parasympathomimetic drugs. It is conceivable that TP-agonists may substantially affect trabecular outflow.
- Published
- 1997
31. A Comparative Study of Thromboxane (TP) Receptor Mimetics and Antagonists on Isolated Human Umbilical Artery and Myometrium
- Author
-
David F. Woodward, Judith Senior, Farhat Abbas, Robert M. Burk, Kay Marshall, Achim H.-P. Krauss, and Zayheda Amin
- Subjects
medicine.medical_specialty ,Vascular smooth muscle ,Chemistry ,Thromboxane ,Myometrium ,Prostanoid ,respiratory system ,Thromboxane receptor ,chemistry.chemical_compound ,Thromboxane A2 ,Endocrinology ,Internal medicine ,cardiovascular system ,medicine ,lipids (amino acids, peptides, and proteins) ,Prostaglandin E2 ,Receptor ,medicine.drug - Abstract
Pickles (1967) proposed that up to four different prostanoid types existed. Coleman et al. (1984) developed a working classification for the prostanoid receptors and since then there has been some debate concerning heterogeneity of each receptor. Following on from these studies, extensive work has led to systematic prostanoid receptor classification. The present prostanoid receptor classification is a simple systematic working hypothesis whereby each of the natural prostanoids has its own receptor termed a P receptor where it is at least ten times more potent than any of the other natural prostanoids. Thus the prostaglandin E2 (PGE2)-sensitive receptors are termed the EP-receptors, PGF2α FP-receptors, PGD2, DP-receptors, PGI2, IP receptors and the thromboxane A2 (TXA2)-sensitive receptors, TP-receptors (Kennedy et al., 1982). The thromboxane receptor (TP) has been shown to mediate constriction of airway and vascular smooth muscle as well as platelet aggregation but discussion has failed to resolve the number of receptors involved.
- Published
- 1997
32. Evidence for human thromboxane receptor heterogeneity using a novel series of 9,11-cyclic carbonate derivatives of prostaglandin F2 alpha
- Author
-
Linda L. Gibson, Achim H.-P. Krauss, Judith Senior, Charles E. Protzman, Farhat Abbas, David F. Woodward, Robert M. Burk, Michael B. Roof, Todd S. Gac, Kay Marshall, and Linda S. Williams
- Subjects
Agonist ,Blood Platelets ,medicine.medical_specialty ,Platelet Aggregation ,medicine.drug_class ,Thromboxane ,Receptors, Thromboxane ,Prostaglandin ,In Vitro Techniques ,Dinoprost ,Thromboxane receptor ,chemistry.chemical_compound ,Thromboxane A2 ,Internal medicine ,medicine ,Animals ,Humans ,Vasoconstrictor Agents ,Platelet ,Receptor ,Pharmacology ,Dose-Response Relationship, Drug ,Myometrium ,Muscle, Smooth ,Bridged Bicyclo Compounds, Heterocyclic ,Prostaglandin Endoperoxides, Synthetic ,Endocrinology ,Hydrazines ,chemistry ,15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid ,Prostaglandins F, Synthetic ,Fatty Acids, Unsaturated ,Muscle Contraction ,Research Article - Abstract
1. The pharmacological activity of a novel series of 9,11-cyclic carbonate derivatives of prostaglandin F2 alpha (PGF2 alpha) was investigated in various isolated smooth muscle preparations possessing different prostanoid receptor subtypes as well as in human platelets. Since subdivision of thromboxane (TP-) receptors into vascular/smooth muscle and platelet subtypes is a controversial subject, our studies included a human smooth muscle preparation (myometrium) in addition to the widely used rat aorta and human platelets as TP-receptor preparations. 2. Two members of that series, AGN191976 and AGN192093 were found to be highly potent and selective thromboxane-mimetics. AGN191976 and AGN192093 contracted isolated tissues of the rat thoracic aorta with EC50 values of 0.32 +/- 0.08 and 1.30 +/- 0.53 nM, respectively. Both agonists were at least 10 times more potent than the benchmark TP-agonist, U-46619, in this preparation, whilst being at least 500 times less potent at other prostanoid receptors (DP, EP1, EP3, FP, IP) in vitro. 3. In human myometrial strips from pregnant and non-pregnant donors, both AGN191976 and AGN192093 were potent contractile agonists. The rank order of potency in myometrium of AGN191976 > AGN192093 > U-46619 correlated well with that in the rat aorta. In human platelet-rich plasma (PRP), however, AGN191976 had potent proaggregatory activity (EC50 = 16.3 +/- 1.4 nM), which is a TP-receptor-mediated event, whereas AGN192093 was a much weaker agonist (EC50 = 37.9 +/- 2.0 microM). AGN192093 did not behave as an antagonist in the platelets, since it did not antagonize platelet aggregation induced by ADP, arachidonic acid, U-46619 or AGN191976. In human washed platelets, the activity profile of AGN191976 (EC50 = 4.15 +/- 0.52 nM) and AGN192093 (no aggregation up to 10 microM) was similar to that obtained in PRP. 4. The involvement of TP-receptors was verified with the potent TP-antagonist, SQ29548. SQ29548 (0.1 microM in myometrium; 1 microM in aorta; 1 microM and 10 microM in platelets) antagonized responses to U-46619, AGN191976 and AGN192093 as expected. 5. In conclusion, AGN191976 and AGN192093, both 9,11-cyclic carbonate derivatives of PGF2 alpha, were found to be highly potent and selective thromboxane-mimetics in rat vascular and human myometrial smooth muscle. However, only AGN 191976 was a potent agonist at TP-receptors in human platelets. The differential activity of AGN192093 on TP-receptor-mediated events in platelets and smooth muscle provides further evidence for a subdivision of TP-receptors. AGN192093 appears to be a useful tool for the pharmacological distinction of TP-receptor subtypes.
- Published
- 1996
33. AGN 191976: a novel thromboxane A2-mimetic with ocular hypotensive properties
- Author
-
Todd S. Gac, Linda L. Gibson, Tanwir Shan, L. S. Williams, Achim H.-P. Krauss, David F. Woodward, Charles E. Protzman, June Chen, Ronald K. Lai, and Robert M. Burk
- Subjects
Agonist ,Blood Platelets ,Male ,medicine.medical_specialty ,genetic structures ,Platelet Aggregation ,medicine.drug_class ,Thromboxane ,Guinea Pigs ,Receptors, Thromboxane ,Ocular hypertension ,Capillary Permeability ,Thromboxane A2 ,chemistry.chemical_compound ,Tonometry, Ocular ,Dogs ,Internal medicine ,medicine ,Animals ,Humans ,Vasoconstrictor Agents ,Pharmacology (medical) ,Receptor ,Antihypertensive Agents ,Intraocular Pressure ,Aged ,Pharmacology ,Muscle, Smooth ,Pupil ,medicine.disease ,Receptor antagonist ,Bridged Bicyclo Compounds, Heterocyclic ,eye diseases ,Prostaglandin Endoperoxides, Synthetic ,Ophthalmology ,Macaca fascicularis ,Endocrinology ,Hydrazines ,chemistry ,Prostanoid receptor activity ,15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid ,Fatty Acids, Unsaturated ,Female ,Ocular Hypertension ,sense organs ,Ophthalmic Solutions ,Conjunctiva ,Prostaglandin H2 - Abstract
The possible subdivision of thromboxane A2-sensitive (TP) receptors is currently a controversial subject. We report herein on a novel thromboxane A2 mimetic, AGN 191976, which has almost identical pharmacological activity to the well-characterized prostaglandin H2/thromboxane A2 (PGH2/TxA2) mimetic U-46619, but its effects on intraocular pressure are quite distinct from U-46619. Prostanoid receptor activity was determined in vitro using different smooth muscle assays and platelets. Intraocular pressure was measured tonometrically in ocular normotensive Beagle dogs and Cynomolgus monkeys. Conjunctival microvascular permeability was determined in guinea pigs. Despite closely resembling U-46619 as a potent and selective TP receptor agonist, AGN 191976 was a potent ocular hypotensive in dogs and monkeys whereas U-46619 did not lower IOP in either species. The ocular hypotensive effect of AGN 191976 in dogs was attenuated by pretreatment with the TP receptor antagonist SQ 29548. Thus, the ocular hypotensive effects of AGN 191976 are consistent with TP receptor stimulation. Both TxA2-mimetics caused plasma leakage in the guinea pig conjunctiva. The disparate activities of U-46619 and AGN 191976 in our studies suggest the existence of heterogeneous populations of TP-receptors in the eye.
- Published
- 1995
34. Comparison of leukotriene B4 and D4 effects on human eosinophil and neutrophil motility in vitro
- Author
-
David F. Woodward, Achim H.-P. Krauss, C.S. Spada, and A.L. Nieves
- Subjects
Leukotriene D4 ,Leukotriene B4 ,Neutrophils ,Immunology ,Chemokinesis ,Cell Separation ,Biology ,In Vitro Techniques ,chemistry.chemical_compound ,medicine ,Cell Adhesion ,Immunology and Allergy ,Humans ,Dicarboxylic Acids ,Leukotriene ,Eosinophil cationic protein ,Dose-Response Relationship, Drug ,Chemotaxis ,Cell Biology ,Eosinophil ,Eosinophils ,Chemotaxis, Leukocyte ,medicine.anatomical_structure ,chemistry ,Eosinophil chemotaxis ,SRS-A - Abstract
The motility of isolated normal human peripheral blood eosinophils and neutrophils in response to exogenous leukotrienes B4 and D4 was examined by means of a modified under-agarose technique and a novel quantitative sampling strategy. Leukotriene D4 was a potent chemoattractant for eosinophils, with a significant threshold chemotactic effect evident at 10-10 M. The abolition of eosinophil chemotaxis by the potent and selective peptide-leukotriene-antagonist SK&F 104353 indicated the pharmacological specificity of the leukotriene D4-induced response. The chemokinetic response of eosinophils to leukotriene D4 generally did not differ significantly from spontaneous migratory activity of unstimulated cells. Leukotriene D4 did not, however, alter directed neutrophil motility until a very high concentration (10-5 M) was achieved, although significant neutrophil chemokinesis relative to unstimulated movement was observed over the tested concentration range. Directional emigration of both eosinophils and neutrophils was induced by leukotriene B4 at concentrations as low as 10-8 M. Analysis of leukocyte orientations provided evidence that chemokinetic responses were not being interpreted as indications of chemotactic behavior. These studies suggest that leukotriene D4 may behave as a potent and selective chemoattractant for human eosinophils at physiologically relevant concentrations. J. Leukoc. Biol. 55: 183–191; 1994.
- Published
- 1994
35. Pharmacological Characterization of the Prostanoid FP-Receptor
- Author
-
Achim H.-P. Krauss, Linda S. Williams, Charles E. Protzman, D.F. Woodward, and C. E. Fairbairn
- Subjects
Prostaglandin ,Prostanoid ,chemistry.chemical_element ,Stimulation ,Calcium ,Pharmacology ,Swiss 3T3 Cells ,chemistry.chemical_compound ,chemistry ,cardiovascular system ,medicine ,Extracellular ,Verapamil ,lipids (amino acids, peptides, and proteins) ,Diltiazem ,medicine.drug - Abstract
Investigation of contractile responses of the cat iris sphincter and rat colon and the calcium signal in Swiss 3T3 cells gave the following rank order of potency for natural and synthetic prostanoids in all three preparations: fluprostenol ≥ prostaglandin F2α (PGF2α) > PGD2 > PGE2 > U-46619 > PGI2 > BW245C (=0) with the exception of the rat colon where the rank order for PGD2 and PGE2 was reversed. PGI2 was inactive in Swiss 3T3 cells. These findings indicate that the responses were mediated by a prostanoid FP-receptor. Contractions of cat iris and rat colon induced with fluprostenol or PGF2α were totally dependent on extracellular calcium. Further investigations in the cat iris demonstrated that prostanoid-induced calcium influx occurs through receptor-operated channels. Contractions could be blocked with La3+ or Mn2+, but were unaffected by diltiazem or verapamil. The increase in cytosolic calcium in Swiss 3T3 cells, on the other hand, was mainly derived from intracellular stores. These studies suggest that smooth muscle and mouse fibroblasts utilize different calcium pools upon FP-receptor stimulation.
- Published
- 1993
36. Morphological Changes in the Anterior Eye Segment after Long-Term Treatment with Different Receptor Selective Prostaglandin Agonists and a Prostamide
- Author
-
David F. Woodward, Achim H.-P. Krauss, Elke Lütjen-Drecoll, and Markus Richter
- Subjects
Agonist ,genetic structures ,medicine.drug_class ,Administration, Topical ,Prostaglandin ,Nerve fiber ,Dinoprostone ,chemistry.chemical_compound ,Nerve Fibers ,Anterior Eye Segment ,Trabecular Meshwork ,Peripheral Nervous System ,medicine ,Animals ,Latanoprost ,Antihypertensive Agents ,Intraocular Pressure ,Bimatoprost ,business.industry ,Ciliary Body ,Prostanoic Acids ,Cloprostenol ,Muscle, Smooth ,Anatomy ,Amides ,Lipids ,Macaca fascicularis ,Ciliary muscle ,medicine.anatomical_structure ,chemistry ,Prostaglandins F, Synthetic ,sense organs ,Trabecular meshwork ,Ophthalmic Solutions ,business ,medicine.drug - Abstract
PURPOSE. To investigate long-term changes in the anterior segment of primate eyes treated for one year with different prostaglandin agonists and a prostamide. The results were compared with those obtained after vehicle treatment and in untreated controls. METHODS. Sixteen young cynomolgus monkeys were unilaterally topically treated for 1 year with either bimatoprost 0.03% (prostamide), sulprostone 0.03% (EP3/EP1 agonist), AH13205 0.1% (EP2 agonist), or latanoprost 0.005% (FP agonist), which all lower IOP in this species at the doses applied. Four animals were treated with the vehicle only. In all cases the left eye was treated, the right eye remained untreated. Six monkeys served as untreated controls. Sections from 4 quadrants each of the circumference of the eyes of 16 drug-treated, 4 vehicle-treated and 6 untreated control animals were investigated qualitatively and quantitatively using light- and electronmicroscopy. The area of widened spaces between ciliary muscle bundles, the number of nerve fiber bundles at the muscle tips, and the width and length of the ciliary muscle were quantitated. RESULTS. The general morphology of the ciliary muscle and trabecular meshwork was normal in appearance and shape in all animals, whereas some localized morphologic changes were observed in the drug-treated animals. The changes were found to be similar in all four treatment groups. In the ciliary muscle, there was a significant increase in optically empty spaces between muscle bundles in the anterior portion of the longitudinal and the reticular ciliary muscle compared with untreated and vehicle-treated control animals. Within these spaces, significantly more myelinated nerve fiber bundles were found in drug-treated compared with normal control animals. Ultrastructurally the spaces were partly covered by endotheliallike cells which, in some areas, were in contact with the basement membrane of the microvasculature. In all treatment groups, there were also changes in the trabecular meshwork region. Significant regional differences among the different quadrants of the eyes and quantitative differences between treatment groups were observed. The ciliary epithelium had a normal appearance in all treatment groups. CONCLUSIONS. After one year of treatment with different prostaglandins and a prostamide, uveoscleral outflow pathways are enlarged and appear organized. Conventional outflow routes were also affected. Long-term treatment with AH13205, latanoprost, sulprostone, or bimatoprost also induces sprouting of nerve fibers. (Invest Ophthalmol Vis Sci. 2003;44:4419 ‐ 4426) DOI:10.1167/iovs.02-1281
- Published
- 2003
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.